AF
SAGE

Amalgamated Financial’s Sage Therapeutics SAGE Stock Holding History

Amalgamated Financial’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$297K Buy
+8,978
New +$338K ﹤0.01% 1741

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Amalgamated Financial's SAGE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Sage Therapeutics (SAGE) in Q1 2022: 8,978 shares worth $297K. The stake represents ﹤0.01% of the portfolio and ranks #1741 among its holdings.

212 funds tracked by Wall St. Rank hold SAGE as of Q1 2022.

  • Amalgamated Financial held 8,978 shares of Sage Therapeutics worth $297K as of Q1 2022.
  • Sage Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Sage Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1741 holding.
  • 212 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.